Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study.

Wai Kay SetoThomas Sau-Yan ChanYu-Yan HwangDanny Ka-Ho WongJames FungKevin Sze-Hang LiuHarinder GillYuk-Fai LamEric H Y LauKa-Shing CheungAlbert K W LieChing-Lung LaiYok-Lam KwongMan-Fung Yuen

Published in: Hepatology (Baltimore, Md.) (2017)

HBsAg-negative, anti-HBc-positive patients had a high rate of HBV reactivation after allogeneic HSCT, with determinants of HBV reactivation including age ≥50 years and chronic graft-versus-host disease; treatment strategies based on these parameters may prevent HBV reactivation and subsequent complications. (ClinicalTrials.gov identifier NCT01481649.) (Hepatology 2017;65:1451-1461).

Keyphrases

hepatitis b virus
liver failure
end stage renal disease
newly diagnosed
chronic kidney disease
stem cell transplantation
bone marrow
sars cov
acute myeloid leukemia
peritoneal dialysis
prognostic factors
risk factors
hematopoietic stem cell
patient reported outcomes
patient reported
drug induced